Don't let today's joy be stolen by tomorrow's worries. Tomorrow can steal today, but only if you forget that tomorrow has not yet come. I will be happy and joyful today and tomorrow, tomorrow's worries will just have to wait until tomorrow or maybe even the next tomorrow because I don't have any extra room [...]
According to a press release from the Decatur Memorial Hospital in Decatur Ill., after their having completed a clinical trial evaluating C-11 Choline PET CT and in men who have suffered a biochemical relapse of prostate cancer, they are now offering the C-11 Choline PET CT commercially. C-11 Choline uses an FDA approved tracer which, [...]
Men who have been diagnosed with advanced prostate cancer and as a result are unable to work may be able to qualify for social security disability benefits. Under the current regulations any man who is metastatic, has late stage, and/or terminal prostate cancer should automatically meet the SSA’s eligibility requirements for disability benefits. If you [...]
There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to [...]
Speaking with men who have taken abiraterone (Zytiga, ABI) and enzalutamide (Xtandi, ENZA), at Malecare we sometimes hear reports of both cognitive and mood changes brought on by these two drugs. Evaluating these two problematic side effects researchers have confirmed our experience, both of these drugs can cause these symptoms and that more men reported [...]
Imaging of prostate cancer has been improving by leaps and bounds over the last few years. Current imaging techniques are not sensitive enough to give us an accurate picture of the cancer. This means that we lose predictive abilities and don’t always have adequate information to make the best treatment decisions. It also means, in [...]
UPDATE June &, 2016 4:30 PM EST We won. The Durbin Amendment to save all cancer research funding at the Department of Defense passed 66-32, saving the Congressionally Directed Medical Research Program (CDMRP), which includes an important prostate cancer funding resource. Thank you to everyone from Malecare Cancer Support and all of our partner organizations [...]
When taking hormone therapy (ADT) each of us experiences different side effects and each of us experiences them differently. Anyone experiencing hot flashes, probably the most commonly reported side effect of ADT during hormone therapy (ADT) knows how difficult, embarrassing and uncomfortable they can become as you go through your life. Some men, who find [...]
Malecare not only is the world’s largest prostate cancer support and education organization it also is responsible for prostate cancer research which has been recognized and published by the world’s largest organization of oncologists, the American Society of Clinical Oncologists (ASCO). At the last ASCO GU Conference Malecare presented a poster and had published an [...]
In 2013, Myriad Genetic failed – in a case that was heard in the United States Supreme Court - to patent the BRCA1 and BRCA2 genes. We all have these two genes which, when they mutate, are associated with breast, ovarian and prostate cancers. If Myriad succeeded, they would have controlled patents on these genes [...]
